Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Christian Bacci
1 University of Padua

Potential competing interests: No potential competing interests to declare.

Well designed and well conducted study.

My only concern is about the MRONJ part.

I understand that it is a summary treatment, but the message that can pass can be misunderstood.

It is true that the prevalence of ONJ is higher in the course of denosumab (such as on Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May;80(5):920-943) but its treatment, when it occurs under denosumab, is simpler (as reported on Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ) https://doi.org/10.32388/PBUJ6Z) than under zoledronate…